Verition Fund Management
JSPR icon

Verition Fund Management’s Jasper Therapeutics JSPR Stock Holding History

Verition Fund Management’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-33,219
Closed -$143K – 3752
2025
Q1 		$143K Buy
33,219
+18,169
+121% +$121K ﹤0.01% 3112
2024
Q4 		$322K Sell
15,050
-10,303
-41% -$214K ﹤0.01% 2743
2024
Q3 		$477K Buy
+25,353
New +$505K ﹤0.01% 2360
2021
Q3 		– Sell
-15,180
Closed -$1.51M – 2118
2021
Q2 		$1.51M Buy
15,180
+4,659
+44% +$463K 0.01% 640
2021
Q1 		$1.05M Hold
10,521
– – 0.01% 591
2020
Q4 		$1.05M Sell
10,521
-753
-7% -$74.9K 0.01% 495
2020
Q3 		$1.12M Buy
11,274
+1,274
+13% +$127K 0.02% 354
2020
Q2 		$1.02M Sell
10,000
-7,500
-43% -$733K 0.03% 405
2020
Q1 		$1.67M Buy
+17,500
New +$1.71M 0.07% 191

Other funds holding JSPR

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Verition Fund Management's JSPR Position: Q2 2025 in Review

Verition Fund Management sold out of Jasper Therapeutics (JSPR) in Q2 2025, closing a stake of 33,219 shares — an estimated $143K sold.

Verition Fund Management first reported a position in JSPR in Q1 2020 and held it in 9 quarters. The position peaked at $1.67M in Q1 2020. 65 funds tracked by Wall St. Rank hold JSPR as of Q2 2025.

  • Verition Fund Management reported no remaining Jasper Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Verition Fund Management sold 33,219 Jasper Therapeutics shares in Q2 2025, an estimated $143K.
  • Verition Fund Management first reported a position in Jasper Therapeutics in Q1 2020 and held it in 9 quarters.
  • Verition Fund Management's Jasper Therapeutics position peaked at $1.67M in Q1 2020.
  • 65 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2025.

Based on Verition Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.